[Algodystrophy associated with antitubercular chemotherapy: 22 cases].
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D003523:Cycloserine / Q000009:adverse effects; D004977:Ethambutol / Q000009:adverse effects; D005000:Ethionamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008297:Male; D009536:Niacinamide / Q000627:therapeutic use; D011718:Pyrazinamide / Q000009:adverse effects; D012019:Reflex Sympathetic Dystrophy / Q000139:chemically induced* / Q000517:prevention & control; D012293:Rifampin / Q000009:adverse effects; D014376:Tuberculosis / Q000188:drug therapy; D014804:Vitamin B Deficiency / Q000150:complications
D000995:Antitubercular Agents; D009536:Niacinamide; D011718:Pyrazinamide; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin
Algo-dystrophie de la chimiothérapie anti-tuberculeuse: à propos de 22 observations.